Rhumbline Advisers Aerovate Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 15,084 shares of AVTE stock, worth $41,631. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,084
Previous 14,622
3.16%
Holding current value
$41,631
Previous $432,000
94.21%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding AVTE
# of Institutions
91Shares Held
27.7MCall Options Held
185KPut Options Held
115K-
Ra Capital Management, L.P. Boston, MA9.19MShares$25.4 Million0.23% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA3.76MShares$10.4 Million0.35% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.24MShares$6.18 Million0.56% of portfolio
-
Atlas Venture Life Science Advisors, LLC1.8MShares$4.97 Million0.4% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.41MShares$3.9 Million0.05% of portfolio
About Aerovate Therapeutics, Inc.
- Ticker AVTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,448,100
- Market Cap $67.5M
- Description
- Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...